**Core Concept**
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with dual activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). It is a key drug in the treatment of both HIV and HBV infections.

**Why the Correct Answer is Right**
The correct answer is B because lamivudine has a higher potency against HBV replication than against HIV replication. The IC50 (inhibitory concentration 50) for HBV is significantly lower than for HIV, indicating a more potent effect on HBV. This is due to the differences in the viral replication mechanisms and the target enzymes, with HBV polymerase being more susceptible to lamivudine inhibition.

**Why Each Wrong Option is Incorrect**
**Option A:** This statement is TRUE because lamivudine indeed possesses anti-HIV and anti-HBV activity, making it a valuable drug for treating co-infected patients.

**Option C:** This statement is TRUE because lamivudine should not be used as monotherapy in HBV/HIV co-infected patients, as resistance to lamivudine can develop rapidly in HBV, compromising its effectiveness against HIV.

**Option D:** This statement is TRUE as well, as anti-HBe seroconversion (the transition from HBeAg-positive to anti-HBe-positive status, indicating reduced viral replication) occurs in a minority of patients treated with lamivudine.

**Clinical Pearl / High-Yield Fact**
It's essential to note that lamivudine resistance can develop rapidly in HBV, especially in the absence of adequate viral suppression and monitoring. Regular viral load and resistance testing are crucial to prevent the development of lamivudine resistance in HBV/HIV co-infected patients.

**Correct Answer Line**
✓ Correct Answer: B. Dose lower for blocking HIV replication than HBV replication.